While pharma is testing how therapies are performing in tubes and trials, payers are at the forefront of the drug pricing debate. This panel will discuss how affordability and value should be the centerfold of the discussion, even if we are not talking about pricing. What solutions is pharma eyeing to innovate the value chain, disrupt discovery and boost outcomes?